
|Videos|May 12, 2016
The Long-Term Impact of Biosimilars on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Polycystic Ovary Syndrome Undergoes Name Change: Polyendocrine Metabolic Ovarian Syndrome
2
Amid Mounting Pressure, FDA Commissioner Marty Makary to Resign
3
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
4
From Misdiagnosis to Advocacy: Addressing Bias and Equity in Heart Failure Management
5


































































































































